CN107011357A - A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy - Google Patents
A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy Download PDFInfo
- Publication number
- CN107011357A CN107011357A CN201710211402.XA CN201710211402A CN107011357A CN 107011357 A CN107011357 A CN 107011357A CN 201710211402 A CN201710211402 A CN 201710211402A CN 107011357 A CN107011357 A CN 107011357A
- Authority
- CN
- China
- Prior art keywords
- physalin
- lung
- ethanol
- preparation
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy, belong to pharmaceutical technology field.After process optimization, the extraction of Physalin B, purification yield are 0.07% or so, and gained monomer purity is more than 97%.It can be good at being enriched with lung after Physalin B intravenously administrable, and it has obvious inhibitory action to lung carcinoma cell, this inhibitory action is significantly stronger than cis-platinum (positive drug), and in concentration dependent；Described Physalin B can not be effectively absorbed into vivo by body, therefore the Physalin B and pharmaceutically acceptable auxiliary material component by effective dose can be prepared into solid or liquid preparation, and the treatment of lung tumors disease is used for by parenteral administration route.
Description
Technical field
The invention belongs to tcm field, it is related to anti-tumor active ingredient Physalin B (Physalin in monkey flower
B preparation method) and its application in resisting tumor of lung pharmacy.
Background technology
Cancer is the serious major disease for jeopardizing human health for being only second to angiocardiopathy at present.It is used as the great disease of a class
Disease, cancer includes the different tumour of kind more than 200.Various tumours are occurring morbidity and are having different spies to the reaction for the treatment of
Levy, mechanism is sufficiently complex.Lung cancer is global most common malignant tumour, and with the complication of atmospheric environment in recent years, it is fallen ill
Rate is in the trend risen year by year, and wherein non-small cell lung cancer accounts for the 80% of lung cancer (NSCLC) incidence of disease, it has also become cancer class is dead
First cause [Clin Cancer Res.2009,15 (6):2076-2084.].U.S.'s lung cancer in 2010 and bronchiolar carcinoma
New cases are estimated as 22.252 ten thousand, wherein male 11.675 ten thousand, women 10.577 ten thousand, dead 15.73 ten thousand
[Anticancer Res.12: 1155-1166,1992.].China's new hair lung cancer month 500,000 annual at present, it is pre- by 2025
Meter China will have 1,000,000 patients with lung cancer every year.In unresectable Locally Advanced or remote during most of NSCLC patient assessments
End transfer.For new diagnosis advanced NSCLC patients, the median survival interval of the Combination chemotherapy based on mooring class is 7.4-
9.9 months, the median survival interval of chemotherapy combined bevacizumab treatment was 12.5 months；Second-line chemotherapy medicine, such as pemetrexed and
The middle position progression free survival phase of docetaxel about 2.2-2.9 months, therapeutic effect is not ideal.Clinic expects that a new generation is efficiently low
The antineoplastic of poison is researched and developed, listed as early as possible.
Physalin (Physalins) is to be present in Physalis (Physalis) plant (such as：Wintercherry fruit or calyx, small wintercherry, Ku Zhi
Deng) and other close plants of Solanaceae in a class high oxidation level 13,14- driffractive ring -16,24- ring lumistane class compounds
(C28H30–34O9–12), from 1969 so far, isolated from monkey flower and obtain more than 30 physalin class compounds.
Physalin B are wherein active preferable one, and research shows it to liver cancer HA22T cells, Cervical Cancer HeLa Cells, nasopharynx
Cancer KB cells, the growth of colon cancer Colo-205 cells are respectively provided with better inhibition effect, but rarely have at present to Physalin B
The report of anti-lung cancer activity and its mechanism of action.
Early stage on Physalin B patent (application publication number be CN102633861A (Application No.
201210119268.8) using the method for supercritical extract as extracting method, and it is related to the organic solvents such as chloroform, methanol,
Not only toxicity is big, costly, and is difficult to realize industrialized production.In addition, at present, also not on Physalin B in anti-lung
The announcement of application patent in terms of portion's tumour.
The content of the invention：
The purpose of the present invention exists for prior art to be difficult to realize a kind of the not enough bitter there is provided wintercherry of industrialized production
Plain B preparation method and its application in resisting tumor of lung pharmacy, solve treatment lung tumors disease at present and lack related
The problem of medicine.
In order to achieve the above object, the technical solution adopted in the present invention is as follows：A kind of preparation method of Physalin B,
Obtained by following approach：
(1) monkey flower crushed is taken, circumfluence distillation is carried out in the 60vol% ethanol for being added to 3-5 times of weight
Twice, extract solution, then be concentrated under reduced pressure into no alcohol twice is merged, the ethyl acetate through 1-3 times of volume after concentration is extracted twice, then is closed
And extract twice, by ethyl acetate layer evaporated under reduced pressure, obtain medicinal extract.
(2) medicinal extract for obtaining step (1) is completely dissolved with ethyl acetate, after being adsorbed through D101 macroporous absorbent resins, according to
It is secondary with the water of 10-20 times of column volume, 20vol% ethanol, 40vol% ethanol, 50vol% ethanol, 60vol% ethanol and
70vol% ethanol is eluted, and is collected the progress concentration of 70vol% ethanol elutions part and is evaporated, with 6 after being evaporated:1-3:1 ratio
(silica filler weight：Concentrate weight) separated by normal pressure normal phase silica gel chromatography, it is respectively 30 with volume ratio:1、25:
1、20:1、 15:1、10:1、5:1 petroleum ether and ethyl acetate mixture carries out gradient elution, each gradient elution successively
30 column volumes, the volume ratio for collecting petroleum ether and ethyl acetate is 15:1、10:1 and 5:1 eluent, merging is obtained after being evaporated
To Physalin B crude product, further through acetone recrystallization, Physalin B monomers are produced.
Further, the monkey flower is wintercherry fruit or calyx, wintercherry, small wintercherry Huo Ku Zhi.
It is a further object of the present invention to provide a kind of above-mentioned Physalin B answering in resisting tumor of lung medicine is prepared
With.
Further, described antineoplastic is solid pharmaceutical preparation or liquid preparation.
Further, the method for administration of the resisting tumor of lung medicine is non-bowel.
Beneficial effects of the present invention are as follows：The Physalin B of the present invention are can be from Physalis (Physalis) plant
(such as small wintercherry (Physalis minima), wintercherry (Physalis alkekengi), Ku Zhi (Physalis angulata)
Deng) in isolate and purify what is obtained, easy to operate and purity is high.In addition, with wide material sources, the advantages of materials are convenient is easy to work
Industryization is largely prepared.Applications of the Physalin B in resisting tumor of lung medicine is prepared has significant effect of anti-lung cancer, by
Resisting tumor of lung pharmaceutical preparation prepared by Physalin B has very strong realistic meaning.The present invention is by chromatography and simply
Recrystallization technology extracts and is prepared for Physalin B crystal, and this technique simplifies the preparation flow of Physalin B, prepared acid
Starching bitter principle B has higher resisting tumor of lung activity.
Brief description of the drawings
Fig. 1 is Physalin B HPLC-DAD detection collection of illustrative plates (230nm)；
Fig. 2 is Physalin B second order mses figure (positive ion mode)；
Fig. 3 (a) is various concentrations Physalin B to A549 cell growth inhibition design sketch；(b) it is various concentrations
Cis-platinum is to A549 cell growth inhibitory action design sketch；
Fig. 4 (a) is influence figures of the various concentrations Physalin B to A549 Apoptosis；Fig. 4 (b) is various concentrations
Influence figures of the Physalin B to ratio shared by Sub-G1 phases in the A549 cell cycles.
Embodiment
The invention discloses applications of the Physalin B in lung tumors medicine is prepared, those skilled in the art can borrow
Reflect present disclosure, is suitably improved.In particular, all similar replacements and change are to those skilled in the art
For be it will be apparent that they are considered as being included in the invention.The application of the present invention is entered by preferred embodiment
Description is gone, related personnel can substantially not depart from present invention, application as described herein changed in spirit and scope
Move or suitably change with combining, to realize and apply the technology of the present invention.
Embodiment 1Physalin B preparation：
(1) extract：
The place calyx 5kg of dry wintercherry fruit or calyx (Physalis alkekengi) is taken, is added in 60vol% ethanol 15L and carries out
Twice, backflow 2 hours, merge extract solution, then be concentrated under reduced pressure into no alcohol twice to circumfluence distillation every time, and 1 times of volume is added after concentration
Ethyl acetate extract 2 times, remerge extract twice, then by ethyl acetate layer evaporated under reduced pressure, obtain 560g medicinal extract.
(2) purify：
The medicinal extract that step (1) is obtained is completely dissolved with ethyl acetate, after being adsorbed through D101 macroporous absorbent resins, is used successively
Water, 20vol% ethanol, 40vol% ethanol, 50vol% ethanol, 60vol% ethanol and the 70vol% ethanol of 10 times of column volumes are washed
It is de-, 70vol% ethanol elutions part is collected, is concentrated under reduced pressure, is evaporated, obtain powder 375kg.With 6:1 ratio (silica filler weight
Amount：Concentrate weight) loading, by normal pressure (atmospheric pressure), normal phase silica gel chromatography is separated, and is respectively 30 with volume ratio:
1、25:1、20:1、15:1、10:1、5:1 petroleum ether and ethyl acetate mixture carries out gradient elution, each gradient successively
30 column volumes are eluted, it is 15 to collect petroleum ether and ethyl acetate volume ratio:1、10:1、5:1 eluent, is incorporated into after doing and obtains
4.6g white powders (principal component content 82.1%), then with acetone recrystallization, obtain the monomeric compound that 3.4g purity is 98.2%
(being calculated using areas of peak normalization method, accompanying drawing 1).
Embodiment 2Physalin B preparation：
(1) extract：
The place calyx 5kg of dry wintercherry fruit or calyx (Physalis alkekengi) is taken, is added in 60vol% ethanol 25L and carries out
Twice, backflow 2 hours, merge extract solution, then be concentrated under reduced pressure into no alcohol twice to circumfluence distillation every time, and 3 times of volumes are added after concentration
Ethyl acetate extract 2 times, remerge extract twice, then by ethyl acetate layer evaporated under reduced pressure, obtain 582g medicinal extract.
(2) purify：
Medicinal extract ethyl acetate dissolves, with D101 macroporous absorbent resins adsorb after, successively with the water of 20 times of column volumes,
20vol% ethanol, 40vol% ethanol, 50vol% ethanol, 60vol% ethanol and 70vol% ethanol elutions, collect 70vol%
Ethanol elution part, is concentrated under reduced pressure, and is evaporated, and obtains powder 381kg.With 3:1 ratio (silica filler weight：Concentrate weight) on
Sample, by normal pressure (atmospheric pressure), normal phase silica gel chromatography is separated, and is respectively 30 with volume ratio:1、25:1、20:1、15:
1、10:1、5:1 petroleum ether and ethyl acetate mixture carries out gradient elution successively, each 30 column volumes of gradient elution,
It is 15 to collect petroleum ether and ethyl acetate volume ratio:1、10:1、5:1 eluent, is incorporated into after doing and obtains 5.3g white powders (master
Component content 79.1%), then with acetone recrystallization, obtain the monomeric compound that 4.2g purity is 97.3%.
The Structural Identification of embodiment 3：
Analyzed through ESI-TOFMS and obtain the molecular weight of the compound for m/z：510.1897, corresponding molecular formula is C28H30O9,
Secondly level mass spectrogram shows that (shown in Fig. 2) major daughter ions are 493,475,451 and 171 etc..13C-NMR spectrums (100MHz,
DMSO-d6) in provide 28 carbon signals, δC160 appear above 4 carbon signals, point out to there may be 4 carbonyls：δC 202.4
For the carbonyl carbon signals (C-1) of α, beta unsaturated ketone on hexatomic ring, δC171.8,167.3 be ester carbonyl group carbon signal (C-18, C-
26), δC209.4 be the carbon signal of ketone.δC106.3 be ketal carbon, and this signal is the feature during physalin class compound carbon is composed
Property signal, it was initially believed that meeting the SPECTROSCOPIC CHARACTERIZATION of physalin class compound.δC126.7,146.1 grip altogether with carbonyl
△2,3；δC135.5,123.4 be △5,6；1H-NMR (400MHz, DMSO-d6) occur in that in spectrum it is many on 3 olefinic carbon atoms
Peak proton signal (δH5.60,5.81,6.90)；Unimodal methyl signals (δ H 1.09, l.16,1.79) on 3 tertiary carbons；δH
2.88 (1H, d, J=4.2, H-25) and δH3.61 (IH, d, J=14.0, H=27) and δH4.27 (1H, dd, J=14.0,
4.2, H-27), thus it is speculated that the compound has "-OCH2CH- " structure fragments, so as to show that the compound has on C-27 and C-14
The structure of oxygen cyclization.Through with bibliography [Tetrahedron Letters, 1969,10 (22):1765-1766.] middle report
Physalin B comparing, finally determine the compound be Physalin B.
The test of pesticide effectiveness of embodiment 4：
A549 cells are inoculated in 96 orifice plates by mtt assay detection cell proliferation inhibition rate with 1 × 104/hole, treat that cell is pasted
After wall, final concentration of 0~40umol/L Physalin B are separately added into, per the μ l of hole 100, each concentration sets 5 parallel holes,
Cultivate after 24h, the μ l of MTT 10 that 5g/L is added into every hole continue to cultivate 4h, abandon supernatant, the μ l of DMSO 100 are added into every hole
Dissolving crystallized body, is placed in shaking table vibration 30min, after being completely dissolved to blue-purple granule, is determined at the nm wavelength of ELIASA 570
Per hole absorbance (A), and calculate cell proliferation inhibition rate (%)=(1- (medicine feeding hole A values-blank control wells A values))/(control
Hole A values-blank control wells A values) × 100% (n=3).
Result of study is shown in accompanying drawing 3 (a) and (b), shows to handle A549 respectively with various concentrations Physalin B and cis-platinum thin
After born of the same parents 24h, wherein Physalin B IC50 is 5.87umol/L, and after 40umol/L cisplatin treateds, inhibiting rate is only
18.1%.In summary, Physalin B have obvious inhibitory action to A549 cells and this inhibitory action is significantly stronger than
Cis-platinum (positive drug), and in concentration dependent.
The test of pesticide effectiveness of embodiment 5：
Flow cytometer AnnexinV-FITC/PI double-stainings detect apoptosis rate by A549 cells with 1 × 105/
Hole is inoculated in 6 orifice plates, after after cell attachment, being separately added into final concentration of 0,4,8,16 μm of ol/L Physalin B, per hole
1mL, continues to cultivate after 24h, is operated according to AnnexinV-FITC/PI cell apoptosis detection kit specifications, using stream
Formula cell instrument sample introduction determine, logarithm scatter diagram is done according to Annexin V-FITC (X)/PI (Y-axis) fluorescence, can obtain by 4 as
Limit the two-parameter figure of composition：Left upper quadrant (Q1) is the damaging cells produced during cell is collected, and right upper quadrant (Q2) is evening
Phase apoptotic cell and non-viable non-apoptotic cell, left lower quadrant (Q3) are living cells, and right lower quadrant (Q4) is viable apoptotic cell, each quadrant
Cell number be by ratio (n=3) shared in inspection total cell number.
A549 cells are inoculated in 6 orifice plates by the flow cytometer PI decoration methods detection cell cycle with 1 × 105/hole, are treated
After cell attachment, be separately added into final concentration of 0,5,10,20 μm of ol/L Physalin B, per hole 1mL, continue to cultivate after 24 h,
Stop culture, pancreatin digestion washs cell 3 times with cold PBS, 70% pre-cooled ethanol is mixed, 4 DEG C of fixations are stayed overnight, centrifuges, discard second
Alcohol supernatant, the PBS for adding precooling washes precipitation 1 time, and supernatant is removed in centrifugation, adds RNase (50mg/L) 10 μ L/ holes and PI (50mg/
L) 300 μ L/ holes, concussion is mixed, and room temperature, lucifuge reaction 30min, flow cytometer carry out DNA detections, with Modifit softwares point
Analyse the ratio (n=3) of each phase cell cycle.
Result of study：Physalin B are shown in accompanying drawing 4 (a) to the result of the apoptosis-induced effect of A549 cells, 4~
After 40umol/L Physalin B processing 24h, Q2+Q4 phase ratios are gradually increased same with the rise of Physalin B concentration
When, ratio shared by Sub-G1 phases is also gradually increasing (Fig. 4 (b)) in the cell cycle, and has significantly with blank control group compared with
Sex differernce (P<0.01).Prompting Physalin B have concentration dependent to the apoptosis induction effect of A549 cells.
The test of pesticide effectiveness of embodiment 6：
The morphological change cell processing of DAPI nuclei dyeings color method observation Apoptosis is with " embodiment 5 ", Physalin
After B effects 24h, nutrient solution is sucked, with PBS 3 times, the paraformaldehyde liquid for immediately adding 40g/L is fixed after 15min, sucked
Fixer, with PBS 3 times, closing 1h is carried out with Blocking buffer to cell, adds 150uL/ hole primary antibody LC3 (1:
1000/1:500) 4 DEG C of overnight incubations, discard primary antibody, and with PBS 4 times, secondary antibody (FITC, goat, 1 are incubated at room temperature:150)
1h, with PBS 4 times, 1 × PBS+DAPI (1:1000) 15min is dyed under room temperature condition, with PBS 3 times, glycerine envelope
Piece, observation apoptosis morphology and random picture in the case where Olympus-FV1000 is inverted Shuangzi light Laser Scanning Confocal Microscope.
Result of study：After Physalin B various concentrations (5,10,20umol/L) processing A549 cells 24h,
Olympus-FV1000 is inverted under Shuangzi light Laser Scanning Confocal Microscope and observed, it is seen that part cell shrinkage, karyopycnosis, chromatin occurs
The apoptosis morphologies such as aggegation change；The fluorescent value of LC3 antibody (autophagy label) is remarkably reinforced, and cell is acted on by medicine
Autophagocytosis is remarkably reinforced, and concentration dependent is presented, and illustrates the machine for inducing lung carcinoma cell autophagy to be Physalin B antitumaous effects
One of system.
The preparation of the compound Physalin B powder-injection of embodiment 7：
Physalin B 500mg
Mannitol 5.0g
Add 400mL waters for injection to dissolve Physalin B 500mg, add mannitol 5.0g, 500 are settled to after dissolving
ML, aseptic filtration, freeze-drying is produced.
The preparation of the compound Physalin B water for injection injections of embodiment 8：
Physalin B 500mg
Tween-80/PLURONICS F87 50mL/80mL
Inject water to 500mL
Physalin B 500mg are taken to be dissolved in 50mL Tween-80s or 80mL PLURONICS F87s, plus 0.1-0.5%
Activated carbon removes pyrogen removal, after miillpore filter ultrafiltration, adds water for injection to 500mL, filling in ampoule bottle or in infusion bottle,
Lid is sealed/rolls, through after the assay was approved, packaging is produced.
The preparation of the compound Physalin B water for injection injections of embodiment 9：
1.0g cyclodextrin is mixed with 50mL waters for injection, settled solution is formed
1.0g Physalin B are added in above-mentioned solution, are stirred 24 hours
Water for injection is settled to 500mL, with 0.22 μm of membrane filtration it is degerming after, it is filling in ampoule bottle or in infusion bottle,
Lid is sealed/rolls, through after the assay was approved, packaging is produced.
In summary, the embodiment of the present invention provides applications of the Physalin B in resisting tumor of lung medicine is prepared with aobvious
The antitumor action of work, the medicine system of the treatment lung tumors prepared by Physalin B and containing Physalin B extracts
Agent, with very strong realistic meaning.
When the present invention is used to prepare the medicine of resisting tumor of lung, physalin and liquid excipient are prepared into solid or liquid
Body preparation.Preferably the drug injection for the resisting tumor of lung that the present invention is provided is freeze drying powder injection or liquid drugs injection.Present invention system
During the medicine of standby resisting tumor of lung constituted together with the excipient of liquid, liquid excipient used herein is in this area
It is well known that mainly having water, glycerine, propane diols, simple syrup, ethylene glycol, polyethylene glycol, D-sorbite etc..
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.Any reference in claim should not be considered as to the claim involved by limitation.
Claims (5)
1. a kind of preparation method of Physalin B, it is characterised in that obtained by following approach：
(1) monkey flower crushed is taken, is added in the 60vol% ethanol of 3-5 times of weight and carries out circumfluence distillation twice,
Merge extract solution, then be concentrated under reduced pressure into no alcohol twice, the ethyl acetate through 1-3 times of volume after concentration is extracted twice, and remerges two
Secondary extract, by ethyl acetate layer evaporated under reduced pressure, obtains medicinal extract.
(2) medicinal extract for obtaining step (1) is completely dissolved with ethyl acetate, after being adsorbed through D101 macroporous absorbent resins, is used successively
Water, 20vol% ethanol, 40vol% ethanol, 50vol% ethanol, 60vol% ethanol and the 70vol% second of 10-20 times of column volume
Alcohol is eluted, and is collected the progress concentration of 70vol% ethanol elutions part and is evaporated, with 6 after being evaporated:1-3:1 ratio (silica filler
Weight：Concentrate weight) separated by normal pressure normal phase silica gel chromatography, it is respectively 30 with volume ratio:1、25:1、20:1、15:
1、10:1、5:1 petroleum ether and ethyl acetate mixture carries out gradient elution successively, each 30 column volumes of gradient elution,
The volume ratio for collecting petroleum ether and ethyl acetate is 15:1、10:1 and 5:1 eluent, merging obtains Physalin B after being evaporated
Crude product, further through acetone recrystallization, produces Physalin B monomers.
2. the preparation method of the Physalin B described in claim 1, it is characterised in that the monkey flower is wintercherry fruit or calyx, acid
Slurry, small wintercherry Huo Ku Zhi.
3. application of the Physalin B according to claim 1 in resisting tumor of lung medicine is prepared.
4. application of the Physalin B according to claim 3 in resisting tumor of lung medicine is prepared, it is characterised in that institute
The antineoplastic stated is solid pharmaceutical preparation or liquid preparation.
5. application of the Physalin B according to claim 3 in resisting tumor of lung medicine is prepared, it is characterised in that institute
The method of administration for stating resisting tumor of lung medicine is non-bowel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710211402.XA CN107011357A (en) | 2017-03-31 | 2017-03-31 | A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710211402.XA CN107011357A (en) | 2017-03-31 | 2017-03-31 | A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107011357A true CN107011357A (en) | 2017-08-04 |
Family
ID=59444956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710211402.XA Pending CN107011357A (en) | 2017-03-31 | 2017-03-31 | A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107011357A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618539A (en) * | 2021-01-05 | 2021-04-09 | 广东药科大学 | Application of physalin B in preparation of medicine for treating acute lung injury |
| CN114181227A (en) * | 2021-12-13 | 2022-03-15 | 佳木斯大学 | Method for extracting physalin and method for purifying extracting solution thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102633861A (en) * | 2012-04-23 | 2012-08-15 | 南京泽朗医药科技有限公司 | Preparation method of physalin B |
| CN103288846A (en) * | 2013-05-15 | 2013-09-11 | 浙江大学 | Method for extracting and purifying total physalin from physalis plants |
| CN103755719A (en) * | 2013-12-31 | 2014-04-30 | 广东食品药品职业学院 | Physalin B crystal and extraction and preparation methods as well as application of physalin B crystal in preparing anti-inflammatory medicines |
| CN105949272A (en) * | 2016-05-20 | 2016-09-21 | 天津中医药大学 | With a-physalin Y, method for extracting same and application of with a-physalin Y |
-
2017
- 2017-03-31 CN CN201710211402.XA patent/CN107011357A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102633861A (en) * | 2012-04-23 | 2012-08-15 | 南京泽朗医药科技有限公司 | Preparation method of physalin B |
| CN103288846A (en) * | 2013-05-15 | 2013-09-11 | 浙江大学 | Method for extracting and purifying total physalin from physalis plants |
| CN103755719A (en) * | 2013-12-31 | 2014-04-30 | 广东食品药品职业学院 | Physalin B crystal and extraction and preparation methods as well as application of physalin B crystal in preparing anti-inflammatory medicines |
| CN105949272A (en) * | 2016-05-20 | 2016-09-21 | 天津中医药大学 | With a-physalin Y, method for extracting same and application of with a-physalin Y |
Non-Patent Citations (3)
| Title |
|---|
| LEI MA ET AL.: "Withaphysanolide A, a novel C-27 norwithanolide skeleton, and other cytotoxic compounds from Physalis divaricata", 《TETRAHEDRON LETTERS》 * |
| LI QIU ET AL.: "Steroids and Flavonoids from Physalis alkekengi var. franchetii and Their Inhibitory Effects on Nitric Oxide Production", 《JOURNAL OF NATURAL PRODUCTS》 * |
| 林峰等: "锦灯笼中酸浆苦素类化学成分的研究", 《现代药物与临床》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618539A (en) * | 2021-01-05 | 2021-04-09 | 广东药科大学 | Application of physalin B in preparation of medicine for treating acute lung injury |
| CN114181227A (en) * | 2021-12-13 | 2022-03-15 | 佳木斯大学 | Method for extracting physalin and method for purifying extracting solution thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103936590B (en) | Diterpene-kind compound in Euphorbia and pharmaceutical composition thereof and its application in pharmacy | |
| TWI648257B (en) | Compounds from antrodia camphorata, method for preparing the same and use thereof | |
| Chang et al. | Extraction and isolation of alkaloids of Sophora alopecuroides and their anti-tumor effects in H22 tumor-bearing mice | |
| He et al. | Anti-influenza A (H1N1) viral and cytotoxic sesquiterpenes from Carpesium abrotanoides | |
| CN102516344B (en) | Compound with antitumor activity and preparation method and application thereof | |
| CN102311475B (en) | New compound separated from Ganoderma lucidum, preparation method thereof and medicinal purpose thereof | |
| AU2016245659B2 (en) | Phillygenin glucuronic acid derivative, preparation method and application thereof | |
| CN114524825A (en) | Artemisia sphaerocephala lactone A-T, pharmaceutical composition thereof, and preparation method and application thereof | |
| CN105153267A (en) | Novel withanolides compound, novel withanolides compound preparation method and medical application of novel withanolides compound | |
| CN107011357A (en) | A kind of preparation method of Physalin B and its application in resisting tumor of lung pharmacy | |
| CN102030813B (en) | Preparation method and application of yellow ginger zingiberensis saponin having high-efficiency anti-cancer activity | |
| CN102908340B (en) | Isolicoflavonol-containing antitumor drug and application thereof | |
| CN103610682B (en) | The preparation method of 3 Alpha-hydroxy-30-olive-12,20 (29)-diene-28-acid and preparing the application in antitumor drug | |
| CN107674054B (en) | Novel skeleton heteroterpene compounds, preparation method, pharmaceutical composition and anti-tumor application thereof | |
| CN101245089A (en) | Process for producing a pair of novel ginsengenin and its compound body, and preparations thereof | |
| CN103214497A (en) | Physalin A extracting process and medical application thereof | |
| CN105012327A (en) | Application of steroid saponin RCE-4 in preparation of medicines for preventing or treating tumors | |
| CN106008651A (en) | Pharmaceutical composition containing isosorbide dinitrate and medical application of pharmaceutical composition containing isosorbide dinitrate | |
| CN104892721B (en) | A kind of new 19-demethylation toadpoison lactone compound and the application in preparing anti-tumor medicinal preparation thereof | |
| CN106366155A (en) | Novel limonins compound as well as preparation method and medical application thereof | |
| CN103694302B (en) | 2 α, the preparation method of 3 beta-dihydroxyl-30-olea-12,20 (29)-diene-28-acid and preparing the application in antitumor drug | |
| CN100434426C (en) | Chinese sumac lactone A , preparation method and its use in pharmacy | |
| CN102432666B (en) | Novel compound separated from Actinostemma tenerum as well as preparation method and application thereof | |
| CN102600175A (en) | Application of ursolic acid in medicament for treating neoplastic diseases | |
| CN102440985A (en) | Application of bixanthone compound FLBG-1108 or its medicinal salt in preparing anticancer medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170804 |